# Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

> **NCT03409432** · PHASE2 · COMPLETED · sponsor: **John Reneau** · enrollment: 26 (actual)

## Conditions studied

- Lymphomatoid Papulosis
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03409432
- **Lead sponsor:** John Reneau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2025-07-16
- **Final completion:** 2025-07-16
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409432, "Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03409432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*